Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on macular edema secondary to branch retinal vein occlusio
Not Applicable
- Conditions
- Macular edema secondary to branch retinal vein occlusion
- Registration Number
- JPRN-UMIN000001546
- Lead Sponsor
- Shiga University of Medical Science, department of Ophthalmology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
glaucoma ocular pressure more than 21 mmHg inflammation disease diabetic retinopathy history of steroid therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method variation on a logarithm of the minimum angle of resolution and variation on a central retinal thickness 1 month, 3 months, 6 months, 9 months, and 12 months after intravitreal injection.
- Secondary Outcome Measures
Name Time Method fluorescin angiography before and 1 month, 3 months, 6 months, 9 months, and 12 months after intravitreal injection.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bevacizumab's anti-VEGF effects versus triamcinolone's anti-inflammatory actions in BRVO-induced macular edema?
How does intravitreal bevacizumab compare to triamcinolone acetonide in resolving macular edema after BRVO in clinical trials?
Which biomarkers correlate with response to anti-VEGF therapy (e.g., VEGF-A levels) in BRVO patients treated with bevacizumab or triamcinolone?
What are the long-term safety profiles of intravitreal bevacizumab and triamcinolone acetonide for BRVO-related macular edema?
Are combination therapies of anti-VEGF agents and corticosteroids more effective than monotherapy for BRVO-induced macular edema?